U.S. FDA chief tough on e-cigarettes steps down abruptly
Companies, agencies, institutions, etc
Reuters
Food and Drug Administration
FDA
Health and Human Services
HHS
Trump
Juul Labs Inc.
Walgreens Boots Alliance
Kroger Co
Walmart Inc
Deutsche Bank
the Food and Drug Administration’s
Nasdaq Biotechnology
Amgen Inc
Gilead Sciences Inc
the Campaign for Tobacco-Free Kids
British American Tobacco
Imperial Brands
Gottlieb’s
Twitter
Senate
The Washington Post
Congress
Trump’s
the Wall Street Journal
the National Cancer Institute
Yasmeen Abutaleb
All Rights Reserved
People
Scott Gottlieb
Alex Azar
Donald Trump
Mr Gottlieb’s
Matthew Myers
George W. Bush
Greg Walden
Norman Sharpless
Brett Giroir
Tim Ahmann
Chris Kirkham
Helen Reid
Georgina Prodhan
Eric Beech
Jonathan Oatis
Bill BerkrotAll
Groups
Americans
Republican
Physical locations
No matching tags
Places
No matching tags
Locations
U.S.
Connecticut
Circle K
London
Los Angeles
Events
No matching tags
Summary
7 Min ReadWASHINGTON (Reuters) - U.S. Food and Drug Administration Commissioner Scott Gottlieb said on Tuesday that he plans to step down next month, a sudden resignation that calls into question how the agency will handle issues such as surging e-cigarette use among teens and efforts to increase competition in prescription drugs. “Scott’s leadership inspired historic results from the FDA team, which delivered record approvals of both innovative treatments and affordable generic drugs, while advancing important policies to confront opioid addiction, tobacco and youth e-cigarette use,” Health and Human Services (HHS) Secretary Alex Azar said in a statement. “He worked effectively with Congress to find solutions and to improve the quality of life for all of us.” Gottlieb often touted that the agency had approved more than 1,000 generic drugs as evidence that it was helping to curb prescription drug prices, a priority of Trump’s administration.
As said here by Yasmeen Abutaleb